查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1850500

藥物篩檢市場按技術、藥物類型、樣品類型和最終用戶分類－2025-2032年全球預測

Drug Screening Market by Technology, Drug Type, Sample Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，藥物篩檢市場規模將達到 299.8 億美元，複合年成長率為 14.86%。

關鍵市場統計數據
基準年 2024 98.9億美元
預計年份：2025年 113.6億美元
預測年份 2032 299.8億美元
複合年成長率 (%) 14.86%

一個簡潔的策略問題框架，驅動著不斷變化的藥物篩檢環境、相關人員、實驗室和採購決策。

由於技術進步、監管環境的變化以及應用場景從臨床診斷到職場合規性的多元化，藥物篩檢領域正在迅速發展。本概要介紹了正在改變篩檢專案設計、實施和管理方式的核心驅動力，在深入分析之前為讀者提供簡明扼要的指導。它綜合了關鍵發展動態——包括分析平台、檢體處理方法、終端用戶需求以及跨境貿易的影響——從而明確了近期戰略要務。

本導言首先清楚說明了研究範圍和目標，並透過識別關鍵相關人員及其面臨的決策（包括實驗室、製造商、醫療保健提供者、雇主和監管機構）來建立後續章節的框架。它著重強調了技術選擇、樣本工作流程和法規遵從性之間的相互關聯，同時指出了推動技術創新應用的商業性壓力。最後，它概述了用於得出調查方法，使讀者能夠理解後續結論和建議的基礎。

分析正在重新定義全球藥物篩檢進行和管理方式的重大技術、監管和營運變革

近年來，藥物篩檢生態系統發生了多項變革性變化，重塑了其功能和價值提案。首先，分析儀器的進步提高了檢測靈敏度和特異性，從而能夠更快、更準確地識別複雜基質中的物質。其次，數位化工作流程和實驗室資訊學的整合簡化了端到端流程，縮短了周轉時間，同時提高了資料的完整性和可追溯性。第三，向分散式即時偵測模式的轉變擴大了偵測範圍，但也同時在非傳統環境中提出了新的驗證和品質保證要求。

同時，監管環境日趨動態，監管機構不斷完善檢測性能、監管鍊和結果報告的標準，以適應技術發展和公共衛生需求。供應鏈韌性已成為一項策略重點，迫使製造商和服務供應商實現採購和庫存策略的多元化。此外，相關人員對透明度和臨床有效性的期望不斷提高，這也對分析結果及其背景解釋提出了更高的要求。綜上所述，這些變化要求制定適應性策略，在採用技術創新的同時，兼顧嚴格的檢驗和營運擴充性。

評估2025年美國關稅調整如何重塑科學研究設施的供應鏈韌性、籌資策略和營運連續性

2025年關稅及貿易政策調整的實施，為依賴跨境採購試劑、儀器零件和耗材的製造商、經銷商和實驗室帶來了明顯的摩擦。對於供應鏈跨越多個司法管轄區的機構而言，進口關稅的增加及其相關的行政成本延長了採購週期，並迫使其重新審視供應商合約和庫存緩衝。在營運層面，實驗室正在透過審查供應商組合、加快替代供應商的資格認證，以及在某些情況下將部分生產活動遷回國內來應對這些挑戰，以降低關稅波動帶來的風險。

除了採購之外，關稅也在影響價格談判和資本支出決策。買家正在考慮設備的整體擁有成本，這可能會增加進口成本；服務提供者則在重新調整定價模式，以在不犧牲品質的前提下保護淨利率。前置作業時間的延長促使實驗室最佳化預測性訂購，並投資於維護和備件策略，以確保檢測服務的連續性。摘要，政策的轉變已將供應鏈管理從一項戰術性職能提升為一項策略能力，直接影響營運韌性和成本結構。

詳細的細分分析將技術、分析物、樣品類型和最終用戶需求與可操作的檢驗和商業化路徑連結起來

對細分市場的深入分析揭示了不同技術平台、分析物類別、檢體類型和最終用戶類別之間的差異化促進因素，這些因素決定了技術的採用路徑和價值提案。在化學冷光層面，層析法平台仍然是確證檢測的核心，其中氣相層析法在揮發性分析物方面表現出色，而液相層析法具有從極性化合物到非極性化合物的廣泛適用性。免疫測量具有成本效益高的可擴展性和高通量篩選能力，化學發光方法提高了靈敏度，而酵素連結免疫層析法試驗（ELISA）和螢光法則提供了高通量篩檢能力。質譜技術，特別是用於揮發性和熱穩定性化合物的氣相層析-質譜聯用技術以及用於多分析物組合的液相層析-串聯式質譜質譜聯用技術，正逐漸成為最終鑑定的黃金標準。這些平台之間的轉換通常需要在通量、靈敏度和操作複雜性之間進行權衡。

在考慮藥物類型細分時，傳統檢測方法仍側重於興奮劑、鎮靜劑和類大麻素；安非他命和古柯鹼需要完善的確認流程，而鴉片類藥物（細分為可待因、海洛因和氫可酮）則需要能夠區分代謝物並考慮交叉反應的檢測方法。離胺酸和四氫大麻酚是法醫學和臨床環境中的重要目標。檢體類型細分決定了檢測流程的設計。血液和尿液仍然是臨床準確性和歷史可比性的基礎；毛髮具有較長的檢測窗口，非常適合法醫學的時間線；口腔液和唾液便於進行非侵入性的現場篩檢，這會影響證據鍊和確認性檢測。臨床實驗室優先考慮診斷有效性和電子健康記錄整合，戒毒中心強調長期監測和患者參與，刑事鑑定實驗室強調證據的嚴謹性和法庭辯護能力，家庭檢測需要方便用戶使用的界面和清晰的說明，而職場檢測則需要在速度和法規遵從性之間取得平衡。了解這些部分如何相互作用，對於協調產品開發、檢驗通訊協定和商業策略至關重要。

區域比較分析概述了管理體制、採購模式和基礎設施的差異如何導致世界主要地區採取不同的採用策略。

區域動態持續影響技術應用、監管重點和商業策略，美洲、歐洲、中東和非洲以及亞太地區呈現出截然不同的模式。在美洲，完善的實驗室基礎設施和一體化的醫療保健系統支援高效能確認平台的快速普及，而監管機構則強調臨床有效性和資料互通性。該地區私營部門在職場和消費者檢測解決方案方面也高度參與，推動了競爭性商業化模式和產品的多樣化。

歐洲、中東和非洲各地法律規範的差異，要求製造商和服務供應商優先開發能夠滿足不同合規要求的適應性產品。多個市場正在增加對法醫學能力的投資，公共衛生措施也影響篩檢計畫中優先考慮的檢測類型。亞太地區既有成熟市場也有新興市場，加速了擴充性、具成本效益解決方案的需求。隨著相關人員在尋求統一的最佳實踐的同時，努力平衡本地監管限制與國際分析標準，跨區域合作和知識交流變得日益重要。

策略競爭概覽，重點在於將塑造市場定位的創新叢集、夥伴關係模式和服務導向業務轉型。

藥物篩檢生態系統的競爭格局呈現出強勁的態勢，其特點是儀器和檢測化學領域的密集創新，以及將檢測、資訊學和合規支持整合在一起的服務型經濟的蓬勃發展。領先企業正投資於用於高通量篩檢和確證分析的模組化平台，而其他企業則透過整合軟體解決方案來增強結果解讀和監管鏈管理，從而實現差異化競爭。儀器製造商和試劑供應商之間的策略聯盟日益普遍，以確保相容性並加快新檢測方法的驗證速度。

在質譜、照護現場診斷和實驗室自動化等高需求領域，併購、策略聯盟和定向收購不斷重塑競爭格局。此外，監管科學和臨床檢驗測試方面的投資仍然是准入壁壘，尤其是在需要法醫學辯護和臨床認證的領域。最後，以訂閱方式提供託管測試和分析能力的面向服務的經營模式正在擴大市場覆蓋範圍，使小型實驗室和非傳統終端用戶無需大量資本支出即可獲得先進的測試方法。

清晰、優先排序的營運和策略建議，領導者可以實施這些建議以加速推廣應用、降低風險並增強長期競爭力。

產業領導者應優先採取一系列切實可行的措施，以確保在快速變化的環境中保持競爭優勢和營運韌性。首先，企業必須使其產品開發藍圖與檢驗的臨床和法醫學要求保持一致，並投資進行嚴謹的性能研究，以預測監管預期和最終用戶的工作流程。其次，供應鏈多元化和策略性庫存管理，以及針對關稅波動、零件短缺和物流中斷等情況的情境規劃，應成為風險緩解的核心。

第三，各機構應加快採用數位化實驗室資訊系統和分析技術，以提高吞吐量、確保資料完整性並實現關鍵設備的預測性維護。第四，各機構應推行模組化經營模式，將硬體、耗材和服務結合，以創造持續的收入來源，並降低分散用戶的採用門檻。第五，相關人員必須投資於員工培訓和認證項目，以隨著技術的不斷發展保持其專業水平。最後，積極與政策制定者、認證機構和專業協會合作，將有助於制定切實可行的法律規範和標準，從而降低創新者和採購者的不確定性。

對混合方法研究途徑、檢驗步驟以及支持報告循證結論的局限性進行透明描述

本報告的研究結合了與領域專家和最終用戶進行的初步研究和定性研究、結構化的二手資訊綜合以及嚴格的交叉檢驗，以確保得出可靠且可操作的結論。初步研究包括對實驗室主任、採購負責人、監管專家和技術供應商的訪談，以了解實際的限制因素、採購標準和檢驗經驗。二手研究包括同行評審文獻、監管指南、技術白皮書和供應商提交的檢驗摘要，所有這些都經過系統評估，以確保其相關性和方法論的嚴謹性。

我們運用資料三角測量技術來調和公開文獻與醫療服務提供者證詞之間的差異，並進行了敏感性檢驗，以確保我們的定性結論並非由孤立的個案所驅動。在適用情況下，我們開發了案例研究，闡述部署路徑、供應鏈協調和檢驗時間表，以支援我們的建議。最後，我們承認本調查方法的限制：受訪者樣本可能偏向早期採用者，且技術的快速創新可能會縮短戰術性建議的有效期限。為了降低這些風險，本研究強調策略原則和流程導向的建議，旨在使其在技術預期發展軌跡之外仍保持相關性。

綜合各項研究結果，將技術、營運和監管主題連結起來，形成一個可供組織決策和投資使用的實用藍圖。

最後，現代藥物篩檢格局的特點是技術融合加速、監管預期不斷變化以及供應鏈敏感性日益增強。這些因素既為企業差異化創造了機遇，也為業務永續營運帶來了挑戰。卓越的企業將是那些投資於經過檢驗、可互通的技術、構建穩健的採購和維護能力，並將分析技術的進步與臨床、法醫學、職場和消費者等領域的明確用戶提案主張相結合的企業。

展望未來，能否將高靈敏度的確診工具整合到高效的篩檢流程中，並輔以強大的資訊學和品質體系，將決定哪些醫療機構能夠在性能和規模上都處於領先地位。相關人員應將本文的研究結果視為投資、營運和政策參與的策略藍圖，以期在檢測可靠性、週轉時間和成本效益方面取得可衡量的改善。本文提出的建議旨在指導實際行動，同時適應新的技術創新和監管發展。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 在職場整合以人工智慧驅動的質譜平台進行超靈敏檢測
  • 擴大家用套件的種類，方便消費者快速採集唾液及口腔液樣本。
  • 引入基於區塊鏈的監管鏈解決方案，以確保藥物檢測樣本的完整性
  • 法醫學實驗室擴大採用非侵入性毛髮和指甲分析進行更廣泛的檢測
  • 用於同時檢測尿液中新型合成鴉片類藥物和類大麻素的多重免疫檢測方法取得了進展
  • 不同司法管轄區的監管協調推動了照護現場設備核准流程的通訊協定。
  • 將快速口腔液檢測結果與機器學習演算法結合，用於預測成癮治療中的復發風險

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按技術分類的藥物篩檢市場

  • 層析法
    • 氣相層析法
    • 液相層析法
  • 免疫檢測
    • 化學冷光免疫檢測
    • 酶聯螢光測定法
    • 酵素結合免疫吸附試驗
  • 質譜分析
    • 氣相層析法質譜聯用
    • 液相層析-串聯式質譜質譜法

9. 按藥物類型分類的藥物篩檢市場

  • 安非他命
  • 古柯鹼
  • 鴉片類藥物
    • 可待因
    • 海洛因
    • 氫可酮
  • 離胺酸
  • 四氫大麻酚

10. 按樣本類型分類的藥物篩檢市場

  • 血
  • 頭髮
  • 口腔液
  • 唾液
  • 尿

第11章 按最終用戶分類的藥物篩檢市場

  • 臨床實驗室
  • 藥物治療中心
  • 法醫學研究所
  • 家庭測試
  • 職場測試

12. 各地區藥物篩檢市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 藥物篩檢市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國藥物篩檢市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Quest Diagnostics Incorporated
    • Laboratory Corporation of America Holdings
    • Thermo Fisher Scientific Inc.
    • Roche Holding AG
    • Abbott Laboratories
    • Danaher Corporation
    • Bio-Rad Laboratories, Inc.
    • Siemens Healthineers AG
    • Becton, Dickinson and Company
    • Sysmex Corporation
Product Code: MRR-DD6333AE5B92

The Drug Screening Market is projected to grow by USD 29.98 billion at a CAGR of 14.86% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.89 billion
Estimated Year [2025] USD 11.36 billion
Forecast Year [2032] USD 29.98 billion
CAGR (%) 14.86%

Concise framing of the evolving drug screening environment, stakeholders, and the strategic questions driving laboratory and procurement decisions

The drug screening landscape is undergoing rapid evolution driven by technological progress, shifting regulatory expectations, and growing diversity in use cases ranging from clinical diagnostics to workplace compliance. This executive brief introduces the core forces reshaping how screening programs are designed, executed, and governed, offering readers a concise orientation before deeper analysis. It synthesizes key developments across analytical platforms, specimen handling practices, end-user requirements, and cross-border trade influences that together define near-term strategic imperatives.

Beginning with a clear statement of scope and objectives, this introduction frames the subsequent sections by identifying the principal stakeholders-laboratories, manufacturers, healthcare providers, employers, and regulators-and the decisions they face. The narrative emphasizes the interconnectedness of technology selection, sample workflow, and regulatory adherence while highlighting the commercial pressures that drive innovation adoption. Finally, it outlines the methodological approach and the types of evidence used to derive insights, ensuring readers understand the basis for the conclusions and recommendations that follow.

Analysis of the major technological, regulatory, and operational shifts that are redefining how drug screening is performed and governed globally

Recent years have produced several transformative shifts that are redefining the drug screening ecosystem, altering both capability and value propositions. First, advances in analytical instrumentation have accelerated detection sensitivity and specificity, enabling earlier and more accurate identification of substances across complex matrices. Second, the integration of digital workflows and laboratory informatics is streamlining end-to-end processes, reducing turnaround times while improving data integrity and traceability. Third, the movement toward decentralized and point-of-care testing formats has expanded access but has also created new validation and quality-assurance requirements for non-traditional settings.

Concurrently, regulatory landscapes are becoming more dynamic, with authorities refining standards for assay performance, chain-of-custody, and result reporting to match technological possibilities and public health needs. Supply chain resilience has emerged as a strategic priority, prompting manufacturers and service providers to diversify sourcing and inventory strategies. Finally, stakeholder expectations around transparency and clinical relevance are raising the bar for both analytical outcomes and the contextual interpretation of results. Taken together, these shifts necessitate adaptive strategies that balance innovation adoption with rigorous validation and operational scalability.

Assessment of how 2025 tariff shifts in the United States are reshaping supply chain resilience, procurement strategies, and operational continuity in laboratories

The introduction of tariffs and trade policy adjustments in 2025 has created measurable friction for manufacturers, distributors, and laboratories that depend on cross-border sourcing of reagents, instrumentation components, and consumables. For organizations whose supply chains span multiple jurisdictions, increased import duties and associated administrative costs have lengthened procurement cycles and necessitated revisions to supplier contracts and inventory buffers. At the operational level, laboratories are responding by reassessing vendor portfolios, accelerating qualification of alternate suppliers, and in some cases repatriating certain manufacturing activities to reduce exposure to tariff volatility.

Beyond procurement, tariffs have influenced pricing negotiations and capital-expenditure decisions. Buyers are weighing the total cost of ownership for instruments that may now carry incremental import costs, and service providers are recalibrating pricing models to preserve margins without compromising quality. Indirect consequences are also evident: extended lead times are prompting laboratories to optimize predictive ordering and to invest in maintenance and spares strategies that maintain continuity of testing services. In summary, policy shifts have elevated supply chain management from a tactical function to a strategic competency that directly impacts operational resilience and cost structures.

In-depth segmentation analysis linking technologies, analyte targets, sample types, and end-user requirements to practical validation and commercialization pathways

A granular view of segmentation reveals differentiated drivers across technology platforms, analyte classes, specimen types, and end-user categories that determine adoption pathways and value propositions. On the technology axis, chromatography platforms remain central for confirmatory testing, with gas chromatography providing strength in volatile analytes and liquid chromatography offering broad applicability across polar and nonpolar compounds; immunoassays deliver high-throughput screening capability with chemiluminescent approaches offering sensitivity gains while ELISA and fluorescent formats provide cost-effective scalability; mass spectrometry techniques, notably gas chromatography mass spectrometry for volatile and thermal-stable compounds and liquid chromatography-tandem mass spectrometry for multi-analyte panels, are increasingly the gold standard for definitive identification. Transitioning between these platforms often involves trade-offs between throughput, sensitivity, and operational complexity.

When examining drug type segmentation, traditional panels continue to emphasize stimulants, depressants, and cannabinoids, with amphetamines and cocaine requiring robust confirmatory workflows, while opiates-subdivided into codeine, heroin, and morphine-demand assays that distinguish metabolites and account for cross-reactivity. Phencyclidine and tetrahydrocannabinol remain important targets for both forensic and clinical use cases. Sample type segmentation drives procedural design: blood and urine remain foundational for clinical accuracy and historical comparability, hair provides extended detection windows suitable for forensic timelines, and oral fluid and saliva facilitate noninvasive, on-site screening with implications for chain-of-custody and confirmatory testing. End-user segmentation highlights distinct requirements: clinical laboratories prioritize diagnostic validity and integration with electronic health records, drug treatment centers focus on longitudinal monitoring and patient engagement, forensic laboratories emphasize evidentiary rigor and courtroom defensibility, home testing demands user-friendly interfaces and clear instructions, and workplace testing balances speed with legal compliance. Understanding how these segments interact is essential for tailoring product development, validation protocols, and commercial strategies.

Comparative regional intelligence outlining how regulatory regimes, procurement models, and infrastructure differences drive distinct adoption strategies across major global regions

Regional dynamics continue to shape technology uptake, regulatory priorities, and commercial strategies, with distinct patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established laboratory infrastructure and integrated healthcare systems support rapid adoption of high-performance confirmation platforms, while regulatory bodies emphasize clinical validity and data interoperability. This region also demonstrates a high degree of private-sector involvement in workplace and consumer testing solutions, which drives competitive commercialization models and service diversification.

Across Europe, Middle East & Africa, regulatory frameworks are heterogeneous, prompting manufacturers and service providers to prioritize adaptable products that can meet divergent compliance requirements. Investment in forensic capabilities is growing in several markets, and public-health initiatives are influencing the types of assays prioritized for screening programs. In the Asia-Pacific region, a mix of mature and emerging markets is accelerating demand for scalable, cost-efficient solutions; local manufacturing capabilities and government-led procurement strategies shape pricing and distribution dynamics. Cross-region collaboration and knowledge exchange are increasingly important as stakeholders seek harmonized best practices that balance local regulatory constraints with international analytical standards.

Strategic competitive overview highlighting innovation clusters, partnership models, and service-oriented business transformations that influence market positioning

Competitive dynamics in the drug screening ecosystem are characterized by concentrated innovation in instrumentation and assay chemistries, alongside a proliferating services economy that bundles testing, informatics, and compliance support. Leading organizations are investing in modular platforms that accommodate both high-throughput screening and confirmatory analyses, while others are differentiating through integrated software solutions that enhance result interpretation and chain-of-custody management. Strategic collaborations between instrument manufacturers and reagent suppliers are becoming more common to ensure compatibility and to accelerate time-to-validation for new assays.

Mergers, strategic partnerships, and targeted acquisitions continue to reshape the competitive landscape as companies seek capabilities in high-demand areas such as mass spectrometry, point-of-care diagnostics, and laboratory automation. Additionally, investments in regulatory science and clinical validation studies serve as durable barriers to entry, particularly in sectors where forensic defensibility or clinical accreditation is required. Finally, service-oriented business models that offer managed testing and subscription-based access to analytic capacity are increasing market reach, enabling smaller laboratories and non-traditional end users to access advanced testing modalities without large capital expenditures.

Clear and prioritized operational and strategic recommendations that leaders can implement to accelerate adoption, reduce risk, and strengthen long-term competitiveness

Industry leaders should prioritize a set of actionable measures to secure competitive advantage and operational resilience in a rapidly evolving environment. First, firms must align product development roadmaps with validated clinical and forensic requirements, investing in rigorous performance studies that anticipate regulatory expectations and end-user workflows. Second, supply chain diversification and strategic inventory management should be elevated to core risk-mitigation practices, with scenario planning for tariff fluctuations, component shortages, and logistics disruptions.

Third, adoption of digital laboratory information systems and analytics should be accelerated to improve throughput, ensure data integrity, and enable predictive maintenance of critical instrumentation. Fourth, organizations should pursue modular business models that combine hardware, consumables, and services to create recurring revenue streams and to lower adoption barriers for decentralized users. Fifth, stakeholders must invest in workforce training and certification programs that maintain proficiency as technologies evolve. Finally, proactive engagement with policymakers, accreditation bodies, and professional associations will help shape practical regulatory frameworks and standards, reducing uncertainty for innovators and purchasers alike.

Transparent explanation of the mixed-methods research approach, validation steps, and limitations that underpin the report's evidence-based conclusions

The research behind this report combines primary qualitative engagements with subject-matter experts and end users, structured secondary-source synthesis, and rigorous cross-validation to ensure robust and actionable findings. Primary inputs included interviews with laboratory directors, procurement leads, regulatory specialists, and technology vendors to capture real-world constraints, procurement criteria, and validation experiences. Secondary research encompassed peer-reviewed literature, regulatory guidances, technical whitepapers, and provider-submitted validation summaries, all systematically evaluated for relevance and methodological rigor.

Data triangulation techniques were used to reconcile discrepancies between public literature and practitioner accounts, and sensitivity checks were applied to qualitative conclusions to ensure they were not driven by isolated anecdotes. Where applicable, case studies illustrating deployment pathways, supply chain adjustments, and validation timelines were developed to anchor recommendations. Finally, the methodology acknowledges limitations: respondent samples may over-represent early adopters, and rapid technological change can shorten the shelf life of tactical recommendations. To mitigate these risks, the study emphasizes strategic principles and process-oriented recommendations designed to remain relevant across expected technology trajectories.

Concluding synthesis that ties together technological, operational, and regulatory themes into a pragmatic blueprint for organizational decision-making and investment

In closing, the contemporary drug screening landscape is defined by accelerated technological convergence, shifting regulatory expectations, and heightened supply chain sensitivity. These forces create both opportunities for differentiation and challenges to operational continuity. Organizations that excel will be those that invest in validated, interoperable technologies; that build resilient procurement and maintenance capabilities; and that translate analytical advances into clear user-value propositions across clinical, forensic, workplace, and consumer contexts.

Looking forward, the capacity to integrate high-sensitivity confirmatory tools with efficient screening workflows, supported by robust informatics and quality systems, will determine which providers lead in both performance and scale. Stakeholders should interpret the findings herein as a strategic blueprint for aligning investment, operations, and policy engagement to achieve measurable improvements in test reliability, turnaround, and cost-efficiency. The recommendations provided are intended to guide pragmatic action while remaining adaptable to emerging innovations and regulatory developments.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-driven mass spectrometry platforms for ultrasensitive drug screening in workplace testing
  • 5.2. Expansion of at-home saliva and oral fluid collection kits for rapid consumer drug screening
  • 5.3. Deployment of blockchain-based chain-of-custody solutions to ensure integrity of drug test samples
  • 5.4. Rising adoption of noninvasive hair and fingernail analysis for extended window drug screening in forensic labs
  • 5.5. Advancements in multiplex immunoassay panels for simultaneous detection of emerging synthetic opioids and cannabinoids in urine
  • 5.6. Regulatory harmonization across jurisdictions driving standardized protocols for point-of-care drug screening device approvals
  • 5.7. Integration of machine learning algorithms with oral fluid rapid test results for predictive relapse risk assessment in addiction treatment

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Screening Market, by Technology

  • 8.1. Chromatography
    • 8.1.1. Gas Chromatography
    • 8.1.2. Liquid Chromatography
  • 8.2. Immunoassay
    • 8.2.1. Chemiluminescent Immunoassay
    • 8.2.2. Enzyme-Linked Fluorescent Assay
    • 8.2.3. Enzyme-Linked Immunosorbent Assay
  • 8.3. Mass Spectrometry
    • 8.3.1. Gas Chromatography Mass Spectrometry
    • 8.3.2. Liquid Chromatography-Tandem Mass Spectrometry

9. Drug Screening Market, by Drug Type

  • 9.1. Amphetamines
  • 9.2. Cocaine
  • 9.3. Opiates
    • 9.3.1. Codeine
    • 9.3.2. Heroin
    • 9.3.3. Morphine
  • 9.4. Phencyclidine
  • 9.5. Tetrahydrocannabinol

10. Drug Screening Market, by Sample Type

  • 10.1. Blood
  • 10.2. Hair
  • 10.3. Oral Fluid
  • 10.4. Saliva
  • 10.5. Urine

11. Drug Screening Market, by End User

  • 11.1. Clinical Laboratories
  • 11.2. Drug Treatment Centers
  • 11.3. Forensic Laboratories
  • 11.4. Home Testing
  • 11.5. Workplace Testing

12. Drug Screening Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Drug Screening Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Drug Screening Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Quest Diagnostics Incorporated
    • 15.3.2. Laboratory Corporation of America Holdings
    • 15.3.3. Thermo Fisher Scientific Inc.
    • 15.3.4. Roche Holding AG
    • 15.3.5. Abbott Laboratories
    • 15.3.6. Danaher Corporation
    • 15.3.7. Bio-Rad Laboratories, Inc.
    • 15.3.8. Siemens Healthineers AG
    • 15.3.9. Becton, Dickinson and Company
    • 15.3.10. Sysmex Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG SCREENING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DRUG SCREENING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG SCREENING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS DRUG SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL DRUG SCREENING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. DRUG SCREENING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. DRUG SCREENING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DRUG SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DRUG SCREENING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DRUG SCREENING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG SCREENING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DRUG SCREENING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG SCREENING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DRUG SCREENING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG SCREENING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DRUG SCREENING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED FLUORESCENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED FLUORESCENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED FLUORESCENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED FLUORESCENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED FLUORESCENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED FLUORESCENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG SCREENING MARKET SIZE, BY COCAINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DRUG SCREENING MARKET SIZE, BY COCAINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG SCREENING MARKET SIZE, BY COCAINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DRUG SCREENING MARKET SIZE, BY COCAINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG SCREENING MARKET SIZE, BY COCAINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DRUG SCREENING MARKET SIZE, BY COCAINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG SCREENING MARKET SIZE, BY CODEINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DRUG SCREENING MARKET SIZE, BY CODEINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG SCREENING MARKET SIZE, BY CODEINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DRUG SCREENING MARKET SIZE, BY CODEINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG SCREENING MARKET SIZE, BY CODEINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DRUG SCREENING MARKET SIZE, BY CODEINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG SCREENING MARKET SIZE, BY HEROIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DRUG SCREENING MARKET SIZE, BY HEROIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG SCREENING MARKET SIZE, BY HEROIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DRUG SCREENING MARKET SIZE, BY HEROIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG SCREENING MARKET SIZE, BY HEROIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DRUG SCREENING MARKET SIZE, BY HEROIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG SCREENING MARKET SIZE, BY MORPHINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DRUG SCREENING MARKET SIZE, BY MORPHINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRUG SCREENING MARKET SIZE, BY MORPHINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DRUG SCREENING MARKET SIZE, BY MORPHINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRUG SCREENING MARKET SIZE, BY MORPHINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DRUG SCREENING MARKET SIZE, BY MORPHINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG SCREENING MARKET SIZE, BY PHENCYCLIDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DRUG SCREENING MARKET SIZE, BY PHENCYCLIDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DRUG SCREENING MARKET SIZE, BY PHENCYCLIDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DRUG SCREENING MARKET SIZE, BY PHENCYCLIDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DRUG SCREENING MARKET SIZE, BY PHENCYCLIDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DRUG SCREENING MARKET SIZE, BY PHENCYCLIDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DRUG SCREENING MARKET SIZE, BY TETRAHYDROCANNABINOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DRUG SCREENING MARKET SIZE, BY TETRAHYDROCANNABINOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DRUG SCREENING MARKET SIZE, BY TETRAHYDROCANNABINOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DRUG SCREENING MARKET SIZE, BY TETRAHYDROCANNABINOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DRUG SCREENING MARKET SIZE, BY TETRAHYDROCANNABINOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DRUG SCREENING MARKET SIZE, BY TETRAHYDROCANNABINOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DRUG SCREENING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DRUG SCREENING MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DRUG SCREENING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DRUG SCREENING MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DRUG SCREENING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DRUG SCREENING MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DRUG SCREENING MARKET SIZE, BY HAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DRUG SCREENING MARKET SIZE, BY HAIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DRUG SCREENING MARKET SIZE, BY HAIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DRUG SCREENING MARKET SIZE, BY HAIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DRUG SCREENING MARKET SIZE, BY HAIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DRUG SCREENING MARKET SIZE, BY HAIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DRUG SCREENING MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DRUG SCREENING MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DRUG SCREENING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DRUG SCREENING MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DRUG SCREENING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DRUG SCREENING MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DRUG SCREENING MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DRUG SCREENING MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DRUG SCREENING MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DRUG SCREENING MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DRUG SCREENING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DRUG SCREENING MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DRUG SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DRUG SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DRUG SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DRUG SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DRUG SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DRUG SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DRUG SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DRUG SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TREATMENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TREATMENT CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TREATMENT CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TREATMENT CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TREATMENT CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TREATMENT CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DRUG SCREENING MARKET SIZE, BY FORENSIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DRUG SCREENING MARKET SIZE, BY FORENSIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DRUG SCREENING MARKET SIZE, BY FORENSIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DRUG SCREENING MARKET SIZE, BY FORENSIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DRUG SCREENING MARKET SIZE, BY FORENSIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DRUG SCREENING MARKET SIZE, BY FORENSIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DRUG SCREENING MARKET SIZE, BY HOME TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DRUG SCREENING MARKET SIZE, BY HOME TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DRUG SCREENING MARKET SIZE, BY HOME TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DRUG SCREENING MARKET SIZE, BY HOME TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DRUG SCREENING MARKET SIZE, BY HOME TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DRUG SCREENING MARKET SIZE, BY HOME TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DRUG SCREENING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DRUG SCREENING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS DRUG SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS DRUG SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS DRUG SCREENING MARKET SIZE, BY OPIATES, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS DRUG SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS DRUG SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE DRUG SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE DRUG SCREENING MARKET SIZE, BY OPIATES, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE DRUG SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE DRUG SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY OPIATES, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. AFRICA DRUG SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 320. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 323. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 324. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 325. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 326. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 327. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2024 (USD MILLION)
  • TABLE 330. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY OPIATES, 2025-2032 (USD MILLION)
  • TABLE 331. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 332. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 333. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. GLOBAL DRUG SCREENING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 336. GLOBAL DRUG SCREENING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 337. ASEAN DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 338. ASEAN DRUG SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 339. ASEAN DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 340. ASEAN DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 341. ASEAN DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 342. ASEAN DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 343. ASEAN DRUG SCREE